DOP058 Pharmacokinetic and pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: Additional results from the GEMINI 1 and 2 studiesM. Rosario, Irving H. Fox, Brian G. Feagan et al.|Journal of Crohn s and Colitis|2014Cited by 24
P234 Vedolizumab does not reduce the CD4+:CD8+ ratio in the CSF of healthy volunteersCatherine Milch, Irving H. Fox, T. Wyant et al.|Journal of Crohn s and Colitis|2012Cited by 7
P164 - Clinical pharmacology of vedolizumab (MLN0002) in patients with active ulcerative colitisCatherine Scholz, Lisa Von Moltke, T. Wyant et al.|Journal of Crohn s and Colitis|2009Cited by 4
P130 - Gastrointestinal selectivity of vedolizumab (MLN0002), a humanized monoclonal antibody to α 4β 7 integrinA. Parikh, Irving H. Fox, Catherine Milch et al.|Journal of Crohn s and Colitis|2009Cited by 1